Bausch + Lomb Corp
NYSE:BLCO
Bausch + Lomb Corp
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery.
Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery.
Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.
Record Q4 Performance: Bausch + Lomb delivered its highest-ever quarterly revenue of $1.405 billion (up 7%) and adjusted EBITDA of $330 million (up 27%) in Q4 2025.
Margin Expansion: Adjusted EBITDA margin reached a record 23.5% in Q4, with full-year margin at 17.5%, both showing significant improvement and exceeding targets.
Strong Guidance for 2026: Management guided 2026 revenue of $5.375–5.475 billion (up 5–7%) and adjusted EBITDA of $1–1.05 billion, projecting further margin growth to about 19%.
Miebo Outperformance: Miebo, a key dry eye medication, delivered $316 million in 2025 revenue, with year-over-year prescription growth of 113%. Peak sales expectations were raised to exceed $600 million.
Pipeline and Innovation: The company highlighted successful early clinical data for its new contact lens material and several imminent product launches, reinforcing confidence in long-term growth.
Operating Leverage and Efficiency: Structural improvements and cost discipline are generating operating leverage, with SG&A efficiencies and a more fixed cost base supporting margin gains.
Competitive Position: Management expressed confidence in outperforming market growth across pharma, vision care, and surgical segments despite competitive pressures.
